Source: Health Products Regulatory Authority (IE) Revision Year: 2022 Publisher: Laboratoire AGUETTANT, 1 Rue Alexander Fleming, 69007 LYON, France
Pharmacotherapeutic group: adrenergic and dopaminergic agents
ATC code: C01CA03
The vascular effects of noradrenaline in the doses usually used clinically result from the simultaneous stimulation of alpha and beta adrenergic receptors in the heart and vascular system. Except in the heart, its action is predominantly on the alpha receptors. This results in an increase in the force (and in the absence of vagal inhibition) in the rate of myocardial contraction. Peripheral resistance increases and diastolic and systolic pressures are raised.
After intravenous administration noradrenaline has a plasmatic half-life of about 1 to 2 minutes.
Noradrenaline is rapidly cleared from plasma by a combination of cellular reuptake and metabolism. It does not readily cross the blood-brain barrier.
Noradrenaline metabolites are excreted in urine primarily as the sulfate conjugates and, to a lesser extent, as the glucuronide conjugates. Only small quantities of noradrenaline are excreted unchanged.
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
